Jasper Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JSPR research report →
About the company
Jasper Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
- CEO
- Jeetinder Singh Mahal
- IPO
- 2020
- Employees
- 22
- HQ
- Redwood City, CA, US
Price Chart
- Market Cap
- $6.96M
- P/E
- -0.13
- P/S
- 0.00
- P/B
- 2.41
- EV/EBITDA
- 0.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -523.04%
- ROIC
- -564.18%
- Revenue
- $0 · 0.00%
- Net Income
- $-75,801,000 · -6.36%
- EPS
- $-3.95 · 19.22%
- Op Income
- $-80,518,000
- FCF YoY
- -22.19%
- 52W High
- $4.00
- 52W Low
- $0.32
- 50D MA
- $0.70
- 200D MA
- $1.44
- Beta
- 3.00
- Avg Volume
- 534.18K
Get TickerSpark's AI analysis on JSPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 6, 26 | Mahal Jeetinder Singh | other | 500,000 |
| Jan 2, 26 | MARTELL RON | other | 234,000 |
| Jan 2, 26 | Mahal Jeetinder Singh | other | 90,000 |
| Jan 2, 26 | CROSS HERB | other | 90,000 |
| Sep 22, 25 | WIGGANS THOMAS G | buy | 41,000 |
| Sep 22, 25 | WIGGANS THOMAS G | buy | 41,000 |
| Sep 22, 25 | Lucas Svetlana | buy | 20,000 |
| Sep 22, 25 | Lucas Svetlana | buy | 20,000 |
| Sep 22, 25 | MARTELL RON | buy | 41,000 |
| Sep 22, 25 | MARTELL RON | buy | 41,000 |
Our JSPR coverage
Recent articles, reports, and earnings notes.
No research on JSPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JSPR report →Similar companies
Peers in the same neighborhood.